PMID: 16518131Mar 7, 2006Paper

Immunotherapy for Alzheimer's disease and other dementias

Clinical Neuropharmacology
Delphine BocheRoy O Weller

Abstract

The aim of this article is to review the role of immunotherapy in the removal of proteins which accumulate abnormally in neurodegenerative disorders associated with dementia, in particular amyloid-beta accumulation in Alzheimer's disease. In both transgenic mouse models and in two trials of amyloid-beta immunotherapy for human Alzheimer's disease, active immunization with amyloid-beta 1-42 results in the removal of amyloid-beta plaques from the cerebral cortex associated with, in the mouse models, improvement in cognitive function. Cerebral amyloid angiopathy and neurofibrillary tangles persist, however, and there is also concern about T lymphocyte immune reactions in the meninges in the human cases. Active immunization schedules are being developed to minimize T lymphocyte reactions and to maximize antibody production and passive immunization protocols are being devised. Immunotherapy for removal of the proteins which accumulate in other neurodegenerative disorders associated with dementia such as prion proteins and alpha-synuclein are in the early stages of development. Dementias in the elderly are an increasing medical, social and economic problem and current treatments are only effective. In the majority of dementias, prote...Continue Reading

References

Jul 11, 2002·The American Journal of Pathology·Einar M SigurdssonThomas Wisniewski
Oct 3, 2002·Nature Reviews. Neuroscience·Dale Schenk
Nov 16, 2002·Science·M PfeiferM Jucker
Sep 25, 2003·Neurological Research·Roy O Weller, James A Nicoll
Oct 10, 2003·Journal of Neuropathology and Experimental Neurology·Tamas ReveszJanice L Holton
Dec 4, 2003·Neurobiology of Aging·Salvatore OddoFrank M LaFerla
Feb 3, 2004·Annals of Neurology·Jessica A EngSteven M Greenberg
Jul 16, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Einar M SigurdssonThomas Wisniewski
Jan 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael G AgadjanyanDavid H Cribbs
Jan 26, 2005·The Journal of Clinical Investigation·Robert P BrendzaDavid M Holtzman

❮ Previous
Next ❯

Citations

Apr 21, 2011·Expert Opinion on Biological Therapy·Hossein Samadi, David Sultzer
Mar 31, 2009·Angewandte Chemie·Roland Jakob-Roetne, Helmut Jacobsen
Jan 6, 2009·Advanced Drug Delivery Reviews·Noemi CsabaMaria Jose Alonso

❮ Previous
Next ❯

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.